Screener
Viking Therapeutics VKTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $608,242 | $715,729 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $67,183 | $53,251 |
| Other accrued liabilities | 39,142 | 23,279 |
| Lease liability, current | — | 137 |
| Total current liabilities | 106,325 | 76,667 |
| Total liabilities | 106,325 | 76,667 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's accounts payable?
- Viking Therapeutics (VKTX) reported accounts payable of $67.18M in Q1 2026.
- How has Viking Therapeutics's accounts payable changed year-over-year?
- Viking Therapeutics's accounts payable increased by 772.3% year-over-year, from $7.7M to $67.18M.
- What is the long-term trend for Viking Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Viking Therapeutics's accounts payable has grown at a 67.9% compound annual growth rate (CAGR), from $3.99M to $53.25M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Viking Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude